background. currently, no data are available on the burden of morbidity and mortality in people with HIV-1 (PWH) harboring a 4-class drug-resistant (4DR) virus (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors). the study aimed to assess the incidence of clinical events and death in this population. methods. this was a cohort study on PWH from the prestigio registry with a documented 4DR virus. burden of disease was defined as the occurrence of any new event including an AIDS-defining event (ADE) or non-AIDS-defining event (NADE) or death from any cause after 4DR evidence (baseline). cox regression models evaluated factors associated with the risk of new clinical events/death. results. among 148 PWH followed for a median (interquartile range) of 47 (32-84) months after 4DR evidence, 38 PWH had 62 new events or died from any cause (incidence rate, 9.12/100 person-years of follow-up; 95% CI = 6.85-11.39): 12 deaths (6 AIDS-related and 6 non-AIDS-related), 18 ADEs, 32 NADE5; 20 of the 38 NADEs (45%) of the incident clinical events were malignancies. the 4-year cumulative incidence of death was 6% (95% CI, 3%-13%), and that of >= 1 event or death was 22% (95% CI, 16%-31%). a higher risk of new clinical events/death was more likely in PWH with previous clinical events (adjusted hazard ratio [aHR], 2.67; 95% CI, 1.07-6.67) and marginally associated with lower baseline CD4+/CD8+ ratio (aHR, 0.82; 95% CI, 0.65-1.02). conclusions. PWH harboring 4DR have a high burden of disease with a worrying incidence of malignancies, strongly ad vising for close prevention and monitoring interventions as well as access to innovative therapeutic strategies, especially in people with a history of clinical events and low CD4+/CD8+ ratio.
Galli, L., Parisi, M.r., Poli, A., Menozzi, M., Fiscon, M., Garlassi, E., et al. (2020). Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. OPEN FORUM INFECTIOUS DISEASES, 7(11) [10.1093/ofid/ofaa456].
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry
Santoro, Maria;
2020-11-01
Abstract
background. currently, no data are available on the burden of morbidity and mortality in people with HIV-1 (PWH) harboring a 4-class drug-resistant (4DR) virus (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors). the study aimed to assess the incidence of clinical events and death in this population. methods. this was a cohort study on PWH from the prestigio registry with a documented 4DR virus. burden of disease was defined as the occurrence of any new event including an AIDS-defining event (ADE) or non-AIDS-defining event (NADE) or death from any cause after 4DR evidence (baseline). cox regression models evaluated factors associated with the risk of new clinical events/death. results. among 148 PWH followed for a median (interquartile range) of 47 (32-84) months after 4DR evidence, 38 PWH had 62 new events or died from any cause (incidence rate, 9.12/100 person-years of follow-up; 95% CI = 6.85-11.39): 12 deaths (6 AIDS-related and 6 non-AIDS-related), 18 ADEs, 32 NADE5; 20 of the 38 NADEs (45%) of the incident clinical events were malignancies. the 4-year cumulative incidence of death was 6% (95% CI, 3%-13%), and that of >= 1 event or death was 22% (95% CI, 16%-31%). a higher risk of new clinical events/death was more likely in PWH with previous clinical events (adjusted hazard ratio [aHR], 2.67; 95% CI, 1.07-6.67) and marginally associated with lower baseline CD4+/CD8+ ratio (aHR, 0.82; 95% CI, 0.65-1.02). conclusions. PWH harboring 4DR have a high burden of disease with a worrying incidence of malignancies, strongly ad vising for close prevention and monitoring interventions as well as access to innovative therapeutic strategies, especially in people with a history of clinical events and low CD4+/CD8+ ratio.File | Dimensione | Formato | |
---|---|---|---|
ofaa456.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
281.63 kB
Formato
Adobe PDF
|
281.63 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.